Emergent BioSolutions, Inc. (EBS)
11.05
+0.10
(+0.91%)
USD |
NYSE |
Nov 26, 16:00
11.04
-0.02
(-0.14%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 580.35M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 10.17% |
| Valuation | |
| PE Ratio | 8.539 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.7781 |
| Price to Book Value | 0.9963 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.152 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.89% |
Profile
Edit
| Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD. |
| URL | http://www.emergentbiosolutions.com |
| Investor Relations URL | http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-IRHome |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 04, 2026 (est.) |
| Last Earnings Release | Oct. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD. |
| URL | http://www.emergentbiosolutions.com |
| Investor Relations URL | http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-IRHome |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 04, 2026 (est.) |
| Last Earnings Release | Oct. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |